ArticleFrontiers in immunology2021
Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Detailed single-cell mapping of the transcriptional response to a virus infection driven by copy-back viral genomes.PLoS pathogens · 2026Article
- Detailed single-cell mapping of the transcriptional response to a virus infection driven by copy-back viral genomes.bioRxiv : the preprint server for biology · 2026Article
- Classification, functions, evolution, and applications of defective viral genomes.Frontiers in microbiology · 2026Review
- The RIG-I-like receptor family of immune proteins.Molecular cell · 2025Review
- Human brain cell types shape host-rabies virus transcriptional interactions revealing a preexisting pro-viral astrocyte subpopulation.Cell reports · 2025Article
- Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy.Molecular therapy. Nucleic acids · 2025Article
- A broadly adaptable protocol for isolating Kupffer cells from non-model species: application toFrontiers in immunology · 2025Article
- Methods for the Detection, Purification, and Production of Defective Viral Genomes During Respiratory Syncytial Virus Infection.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Mathematical model calibrated toiScience · 2024Article
- High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors.Molecular therapy. Methods & clinical development · 2024Article
- Molecular Analysis of Copy-Back Defective Interfering RNAs of Morbilliviruses.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-CelFrontiers in bioengineering and biotechnology · 2024Article
- A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.Molecular therapy oncolytics · 2023Review
- Exploiting RIG-I-like receptor pathway for cancer immunotherapy.Journal of hematology & oncology · 2023Review
- The host transcriptome change involved in the inhibitory effect of exogenous interferon-γ on Getah virus replication.Frontiers in microbiology · 2023Article
- Friend or foe: RIG- I like receptors and diseases.Autoimmunity reviews · 2022Review
- A Virus Is a Community: Diversity within Negative-Sense RNA Virus Populations.Microbiology and molecular biology reviews : MMBR · 2022Review
- Optimization of VSV-ΔG-spike production process with the Ambr15 system for a SARS-COV-2 vaccine.Biotechnology and bioengineering · 2022Article
- Development of a Singleplex Real-Time Reverse Transcriptase PCR Assay for Pan-Dengue Virus Detection and Quantification.Viruses · 2022Article
- LincRNA-EPS impairs host antiviral immunity by antagonizing viral RNA-PKR interaction.EMBO reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Replication competent vesicular stomatitis virus (VSV) is the basis of a vaccine against Ebola and VSV strains are developed as oncolytic viruses. Both functions depend on the ability of VSV to induce adequate amounts of interferon-α/β. It is therefore important to understand how VSV triggers interferon responses. VSV activates innate immunity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.